National Institute on Aging; Notice of Closed Meetings, 25805-25806 [2017-11497]
Download as PDF
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 106 / Monday, June 5, 2017 / Notices
claiming priority to the aforementioned
applications.
E–006–2007/0, Pletnev et al.,
‘‘Synergistic Internal Ribosome Entry
Site/MicroRNA Based Approach for
Attenuation of Flaviviruses and Live
Vaccine Development,’’ U.S. Provisional
Patent Application Number 62/443,214,
filed January 6, 2017, and U.S. and
foreign patent applications claiming
priority to the aforementioned
applications.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to live
attenuated West Nile Virus vaccines for
use in humans or animals.
West Nile virus (WNV) is a positivestrand RNA virus of the family
Flaviviridae, part of the Japanese
encephalitis virus serocomplex that
includes important human pathogens
such as Murray Valley encephalitis,
Japanese encephalitis, and St. Louis
encephalitis viruses. WNV has been
present in Africa and Asia for decades
and has usually been associated with
mild illness that includes symptoms of
low-grade fever, headache, rash,
myalgia, and arthralgia. Recently, WNV
has spread rapidly across the Western
hemisphere and is now the major
vector-borne cause of viral encephalitis
in the United States. By 2010, 3 million
adults were estimated to have been
infected with WNV in the United States,
with nearly 13,000 cases of
neuroinvasive disease, almost half of
which occurred in adults greater than 60
years of age. In this age group, WNV
infection can cause hepatitis,
meningitis, and encephalitis, leading to
paralysis, coma, and death. WNV is
considered an emerging infection in the
United States and presents a significant
public health threat. This
epidemiological trend of WNV suggests
that the United States can expect
periodic WNV outbreaks, underscoring
the need for a safe and effective vaccine
to protect at-risk populations, especially
older adults.
WNV is also a significant worldwide
public health threat. Starting in the mid1990s, the frequency, severity, and
geographic range of WNV outbreaks
increased, and outbreaks of WNV
meningitis and encephalitis affecting
primarily adults struck Bucharest,
Romania, in 1996, Volgograd, Russia, in
1999, and Israel, in 2000. WNV crossed
the Atlantic and reached the Western
hemisphere in the summer of 1999
when a cluster of patients with
encephalitis was reported in the
metropolitan area of New York City,
VerDate Sep<11>2014
17:31 Jun 02, 2017
Jkt 241001
New York, in the United States, and
within 3 years the virus had spread to
most of the contiguous U.S. and the
neighboring countries of Canada and
Mexico. In addition, although few
human cases have been reported, WNV
has also been found in Central and
South America through surveillance
studies in field specimens, suggesting a
potential risk for an outbreak in
humans. In the approximately eighty
(80) years since its discovery, the virus
has propagated to a vast region of the
globe and is now considered the most
important causative agent of viral
encephalitis worldwide.
No vaccine exists today to prevent
WNV. The methods and compositions of
this invention provide a means for
prevention of WNV infection by
immunization with live attenuated,
immunogenic viral vaccines against
WNV.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Institute of Allergy and Infectious
Diseases receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 24, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–11491 Filed 6–2–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
25805
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Microbiome
and Antibiotic Resistance in Elders Study
(MARvELS).
Date: June 19, 2017.
Time: 1:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 2W200, 7201 Wisconsin
Avenue, Bethesda, MD 20892.
Contact Person: Carmen Moten, Ph.D.,
MPH, Scientific Review Officer, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7703, cmoten@
mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Aging Special Emphasis Panel; A Global
Perspective on Cognition and Dementia.
Date: June 22, 2017.
Time: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 2W200, 7201 Wisconsin
Avenue, Bethesda, MD 20892.
Contact Person: Carmen Moten, Ph.D.,
MPH, Scientific Review Officer, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7703, cmoten@
mail.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Pragmatic
Trials for Dementia Care.
Date: June 23, 2017.
Time: 2:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2W200, 7200
Wisconsin Avenue, Bethesda, MD
(Telephone Conference Call).
Contact Person: Carmen Moten, MPH,
Ph.D., Scientific Review Officer, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7703.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
E:\FR\FM\05JNN1.SGM
05JNN1
25806
Federal Register / Vol. 82, No. 106 / Monday, June 5, 2017 / Notices
Dated: May 30, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–11497 Filed 6–2–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Chris Kornak, J.D., 240–627–3705,
chris.kornak@nih.gov. Licensing
information and copies of the U.S.
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Methods for Treating Cerebral Edema
and Restoring Blood-Brain Barrier
Integrity
Description of Technology: There are
nearly 600 million clinical cases of
Plasmodium falciparum malaria
annually. For most individuals living in
endemic areas, malaria is
uncomplicated and resolves with time.
However, malaria can become severe
and life threatening in young children,
which resulted in 429,000 deaths in
2015. One of the most deadly
complications of P. falciparum infection
is cerebral malaria (HCM) characterized
by the onset of severe neurological signs
such as altered consciousness, seizures,
and coma. Thus, there is an urgent need
for the development of effective
adjunctive therapies that can be used in
VerDate Sep<11>2014
17:31 Jun 02, 2017
Jkt 241001
conjunction with anti-malarials to treat
children with HCM.
The inventors, listed below, have
discovered that glutamine antagonists
can be used to treat mice with
experimental cerebral malaria (ECM) in
conjunction with anti-malarials. It was
found that glutamine antagonist, 6diazo-5-L-norleucine (DON)
successfully restored blood-brain barrier
integrity and decreased brain swelling
in ECM mice. This finding suggests that
glutamine antagonists may be effective
in treating neurological damage in HCM
patients.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Therapeutic for cerebral malaria
Competitive Advantages:
• Effective adjunctive therapeutics for
cerebral malaria are not available.
Development Stage: Pre-Clinical.
Inventors: Susan K. Pierce, NIAID,
NIH, Johnathan Powell, Johns Hopkins
University.
Publications: Gordon, Emile B., et al.
(2015) Targeting glutamine metabolism
rescues mice from late-stage cerebral
malaria. PNAS 112(42): 13075–13080.
Intellectual Property: HHS Reference
No. E–202–2015/0—US Provisional
Patent Application No. 62/175,000 filed
June 12, 2015; PCT Patent Application
No. PCT/US2016/036996 filed June 10,
2016.
Licensing Contact: Chris Kornak, J.D.,
240–627–3705, chris.kornak@nih.gov.
Collaborative Research Opportunity:
For collaboration opportunities, please
contact Chris Kornak, J.D. 240–627–
3705, chris.kornak@nih.gov.
Dated: May 24, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–11492 Filed 6–2–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Research
Project Grants.
Date: June 20, 2017.
Time: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Elena Sanovich, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7351, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–8886,
sanoviche@mail.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Time-Sensitive
Obesity.
Date: June 21, 2017.
Time: 10:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7353, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Preventing Type 2
Diabetes.
Date: June 28, 2017.
Time: 10:00 a.m. to 11:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7353, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK PTH
Receptor (P01).
Date: July 25, 2017.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\05JNN1.SGM
05JNN1
Agencies
[Federal Register Volume 82, Number 106 (Monday, June 5, 2017)]
[Notices]
[Pages 25805-25806]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-11497]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Aging Special Emphasis
Panel; Microbiome and Antibiotic Resistance in Elders Study
(MARvELS).
Date: June 19, 2017.
Time: 1:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, 2W200,
7201 Wisconsin Avenue, Bethesda, MD 20892.
Contact Person: Carmen Moten, Ph.D., MPH, Scientific Review
Officer, National Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7703,
cmoten@mail.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on Aging Special Emphasis
Panel; A Global Perspective on Cognition and Dementia.
Date: June 22, 2017.
Time: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, 2W200,
7201 Wisconsin Avenue, Bethesda, MD 20892.
Contact Person: Carmen Moten, Ph.D., MPH, Scientific Review
Officer, National Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7703,
cmoten@mail.nih.gov.
Name of Committee: National Institute on Aging Special Emphasis
Panel; Pragmatic Trials for Dementia Care.
Date: June 23, 2017.
Time: 2:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, Suite
2W200, 7200 Wisconsin Avenue, Bethesda, MD (Telephone Conference
Call).
Contact Person: Carmen Moten, MPH, Ph.D., Scientific Review
Officer, National Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7703.
(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging
Research, National Institutes of Health, HHS)
[[Page 25806]]
Dated: May 30, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-11497 Filed 6-2-17; 8:45 am]
BILLING CODE 4140-01-P